Media Release
Compelling value upside for Race
A new report by Independent Investment Research suggests that Australian biotech Race Oncology (ASX:RAC) is significantly undervalued.
- Posted by: Race Oncology
Featured
Finance News Network interviews CEO Peter Molloy
CEO Peter Molloy spoke with Finance News Network about Bisantrene and Race Oncology's future prospects.
- Posted by: Race Oncology
FeaturedMedia Release
Race appoints US consultant to drive partnering, investment, clinical funding
Race Oncology is pleased to announce that it has executed an agreement with Mr Tom Lee to assist Race with partnering and funding opportunities in the US, with a focus on Houston, Texas.
- Posted by: Race Oncology
FeaturedMedia Release
Race signs agreement with NSF Health Sciences to file IND
Race Oncology is pleased to announce it has executed an agreement with Washington D.C - based advisory firm, NSF Health Sciences, to facilitate its IND1 filing in the US for leukaemia drug Bisantrene.
- Posted by: Race Oncology
FeaturedMedia Release
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood
- Posted by: Race Oncology
FeaturedMedia Release
Chart: Long-term survival case report of patients treated with Bisantrene Combination Therapy
The chart below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy.
- Posted by: Race Oncology
FeaturedMedia Release
Bisantrene granted unlicensed medicine approval in UK
Race Oncology is pleased to announce that approval has been received from the Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an
- Posted by: Race Oncology